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Abstract
Background: Venous thromboembolism (VTE) is associated with ovarian cancer and may impact
the prognosis of ovarian cancer. Our aims were to examine the extent of disease at the time of the
diagnosis of ovarian cancer and to estimate the impact of VTE on survival of ovarian cancer.
Methods: We identified 12,835 ovarian cancer patients diagnosed from 1980 to 2003 in the
Danish Cancer Registry and obtained information on previous primary VTE diagnosis from the
Danish National Hospital Discharge Registry. Ovarian cancer patients with previous VTE related
to other cancers, surgery, or pregnancy were excluded. The vital status was determined by linking
data to the Civil Registration System.
Results: We identified 50 ovarian cancer patients diagnosed less than 4 months after the VTE and
78 ovarian cancer patients diagnosed more than 4 months after the VTE diagnosis. Advanced stages
tended to be more common among patients with VTE. One-year survivals were 44% and 54%
among the two VTE groups, compared with 63% among patients without VTE. Adjusted (for age,
calendar time, comorbidity, and FIGO-stage) mortality ratios were 1.7 (95% CI = 1.2–2.5) and 1.2
(95% CI = 0.8–1.7), respectively.
Conclusion: Ovarian cancer diagnosed less than four months before VTE is associated with an
advanced stage and a poorer prognosis.
Background
Ovarian cancer has a poor prognosis, and is frequently
complicated by venous thromboembolic events (VTE) [1-
3]. About 70% of ovarian cancers are diagnosed at an
advanced stage [4,5], and advanced stage seems to be
associated with higher risk of thromboembolic events [6].
Occasionally, VTE occurs prior to cancer diagnosis and
research suggests that VTE may occur as a consequence of
an underlying, undiagnosed cancer [7,8].
A recently published, large population-based, study found
that the incidence of unprovoked VTE was almost three
times higher in the year preceding ovarian cancer diagno-
sis [9]. However, a paucity of research has investigated the
Published: 17 July 2006
BMC Cancer 2006, 6:189 doi:10.1186/1471-2407-6-189
Received: 10 March 2006
Accepted: 17 July 2006
This article is available from: http://www.biomedcentral.com/1471-2407/6/189
© 2006 Tetsche et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2006, 6:189 http://www.biomedcentral.com/1471-2407/6/189
Page 2 of 6
(page number not for citation purposes)
effect of VTE on ovarian cancer prognosis. Sorensen et al
[6] reported poorer prognosis among cancer patients fol-
lowing a thrombolic event, however they did not examine
the prognosis for individual cancer sites. Moreover, it is
not clear how the prognosis of ovarian cancer patients is
affected by the timing of the thromboembolic event – i.e.
prior to, or simultaneous to, diagnosis with ovarian can-
cer.
VTE is likely to cause significant morbidity for women
subsequently diagnosed with ovarian cancer, and to have
serious implications for their clinical care. To examine the
impact of VTE on survival of ovarian cancer patients, we
present a population-based study estimating the extent of
disease at ovarian cancer diagnosis, and the impact of VTE
in relation to survival from ovarian cancer.
Methods
Setting and design
We conducted a nationwide registry-based cohort study in
Denmark with a population of approximately 5.4 million
inhabitants. The Danish population has free access to tax-
supported medical care. A unique, 10-digit, civil registra-
tion number (CPR number) is assigned to all Danish citi-
zens at birth, and this number enables unambiguous
linkage between registries. The Civil Registration System is
updated daily, with information on vital status (dead or
alive), and date of death. The Danish Cancer Registry has
recorded all patients in Denmark with malignant neo-
plasms since 1943 [10]. In this registry, the extent of
spread of the ovarian cancer at the time of diagnosis is
classified FIGO-stage I to IV [11] or unknown. The Danish
National Hospital Discharge Registry [12] includes infor-
mation about all patients admitted to nonpsychiatric hos-
pitals in Denmark since 1977.
We included patients who had a diagnosis of ovarian can-
cer (codes 175.0, 175.1, 175.2, 175.3, 375.0, 475.0, or
875.0, in the International Classification of Diseases, 7th revi-
sion) between January 1st 1980 and December 31st 2003
[13], recorded in the Danish Cancer Registry. We identi-
fied 12,875 patients with an incident diagnosis of ovarian
cancer and linked using the CPR number, to the National
Hospital Discharge Registry to identify those who had a
first time hospitalization with a primary VTE (168
patients) before their cancer diagnosis (VTE coded 45099,
45100, in the International Classification of Diseases, 8th ver-
sion; VTE coded DI260, DI269, DI269A, DI801, DI802,
DI802B, DI803, DI803D, DI803E, DI803F, in the Interna-
tional Classification of Diseases, 10th version) [14,15]. We
excluded patients who had 1) a VTE and previous cancer
(11 patients), 2) surgery prior to the incidence of VTE (29
patients), and 3) patients who were pregnant or had given
birth less than nine months before, or three months after,
the VTE (0 patients). The date of the ovarian cancer diag-
nosis was the date of the discharge diagnosis registered in
the National Hospital Discharge Registry. Patients who
developed VTE after the treatment for ovarian cancer were
not included. A total of 12,835 ovarian cancer patients
were included in the study, of which 128 had a diagnosis
of VTE before the ovarian cancer. Information on VTE for
these patients was included from 1 January 1977 to 31
December 2003.
Two mutually exclusive cohorts of ovarian cancer patients
with VTE were defined according to the interval between
the diagnoses of VTE and ovarian cancer. Group 1:
patients in whom ovarian cancer was diagnosed less than
four months after VTE, and, Group 2: patients in whom
ovarian cancer was diagnosed over four months after VTE
(range 4 months to 27 years). We chose four months as a
cut-off, as research indicates a high incidence of unpro-
voked cases of VTE less than four months prior to cancer
diagnosis [9]. For each of the two cohorts of patients with
VTE and ovarian cancer, all other Danish ovarian cancer
patients without a discharge diagnosis of VTE served as a
control cohort. The follow-up period was at least one year
(range 1 to 26 years). Mortality was determined by linkage
to the Civil Registration System.
Statistical analysis
FIGO stage associated with VTE
The prevalence of patients with ovarian cancer and VTE
who had FIGO stage IV disease was compared with the
prevalence of all other ovarian cancer patients who had
FIGO stage IV disease by computing the prevalence ratio
and its associated 95% confidence intervals (CI) (the
prevalence of patients with FIGO stage IV and VTE divided
by the prevalence of patients with FIGO stage IV without
VTE) adjusted for age.
Survival
Patients were followed from the date of the ovarian cancer
diagnosis to death or the end of the follow-up period
(December 31, 2005), whichever was the sooner. We
summarize the survival of ovarian cancer patients using
Kaplan-Meier survival curves. The proportion of patients
surviving at one-year with and without VTE was calculated
along with associated 95% confidence intervals [16].
We used Cox proportional hazards regression to compare
the mortality among the cancer patients with and without
VTE. We computed the hazard ratio (and associated 95%
confidence intervals) as a measure of mortality ratio, sep-
arately, for one year and greater than one year post-diag-
nosis. The diagnostic plot indicated that the mortality
hazards were proportional within these time intervals (1
year and subsequent years), but not over the entire time
period. We adjusted for age (<50 years, 50–69 years, 70–
89 years and 90+ years), year of diagnosis (5-year calendarBMC Cancer 2006, 6:189 http://www.biomedcentral.com/1471-2407/6/189
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periods), comorbidity (Charlson Comorbidity Index; 0,
1–2, 3+) [17], and FIGO stage. All estimates were given
with 95% confidence intervals, which were calculated by
the profile likelihood method. All statistical analyses were
performed using SAS (version 9.1.3, SAS Institute, Cary,
N.C.). The study was approved by the Aarhus University
Registry Board and the Danish Data Protection Agency
(record no. 2004-41-4353).
Results
We identified 128 patients out of 12,835 ovarian cancer
patients who were registered with an ovarian cancer diag-
nosis subsequent to a diagnosis of VTE. Of these 128
patients, 50 were diagnosed with ovarian cancer less than
four months after VTE, an additional 78 had ovarian can-
cer diagnosed more than four months after an episode of
VTE. Characteristics of the ovarian cancer patients are
shown in table 1.
FIGO stage associated with VTE
The proportion of patients with ovarian cancer and VTE
for whom information on stage of disease was available
did not differ much from that of the ovarian cancer
patients without VTE for patients diagnosed less than four
months (Table 2). The distribution of ovarian cancer stage
was slightly shifted toward later stages in the cohorts of
women with VTE compared with the cohort of women
without VTE. Among ovarian cancer patients diagnosed
less than four months after VTE, 34% had stage IV disease,
as compared with 31% of ovarian cancer patients without
VTE (age-adjusted prevalence ratio = 1.1; 95% CI = 0.8–
1.5) (Table 2). Among the patients in whom VTE was
diagnosed more than four months before ovarian cancer,
35% had stage IV disease, as compared with 31% of the
ovarian cancer patients without VTE (age-adjusted preva-
lence ratio = 1.1; 95% CI = 1.0–1.5) (Table 2).
Survival
Figure 1 shows the unadjusted survival curves for patients
in whom ovarian cancer was diagnosed less than four
months after VTE and all other ovarian cancer patients
without VTE. Only 44% (95% CI = 33–60%) of the VTE
patients were alive at one year, in contrast to 63% (95%
CI = 62–64%) of the comparison cohort. The adjusted
mortality ratio was 1.7 (95% CI = 1.2–2.5) for the first
year after the cancer diagnosis (Table 3) and 1.0 (95% CI
= 0.6–1.8) for the period after the first year.
Patients in whom ovarian cancer was diagnosed more
than four months after the episode of VTE also had a
poorer prognosis (Figure 2); 54% (95% CI = 44–66%) of
them were alive at one year, as compared with 63% (95%
CI = 62–64%) of the comparison cohort. The adjusted
mortality ratio was 1.2 (95% CI = 0.8–1.7) for the first
year of follow-up (Table 3) and 1.1 (95% CI = 0.8–1.6) for
the period after the first year.
Discussion
In this registry-based study of patients with ovarian cancer
and VTE, we found that ovarian cancer patients with a
concurrent diagnosis of VTE had a poorer prognosis than
ovarian cancer patients who did not have VTE. This find-
ing could not be explained by differences between the
cohorts in age, calendar-year, comorbidity or FIGO-stage,
Table 1: Characteristics of ovarian cancer patients, N = 12,835.
Ovarian cancer without VTE  Ovarian cancer less than 4 months 
after VTE 
Ovarian cancer 4 months to 27 years 
after VTE 
(N = 12,707) (N = 50) (N = 78)
Median age, years 63 67 71
(25%–75% percentile) (54–73) (58–78) (62–78)
Age groups
<50 years 2,239 (18%) 6 (12%) 9 (12%)
50–69 years 6,328 (50%) 22 (44%) 28 (36%)
70–89 years 4,051 (32%) 22 (44%) 39 (50%)
90+ years 89 (1%) 0 (0%) 2 (3%)
Year of diagnosis
1980–84 2,538 (20%) 10 (20%) 4 (5%)
1985–89 2,711 (21%) 13 (26%) 13 (17%)
1990–94 2,671 (21%) 7 (14%) 20 (26%)
1995–99 2,690 (21%) 7 (14%) 24 (31%)
2000–03 2,097 (17%) 13 (26%) 17 (22%)
Comorbiditya
0 11,289 (89%) 47 (94%) 60 (77%)
1–2 1,361 (11%) 3 (6%) 17 (22%)
3+ 57 (<1%) 0 1 (1%)
a Charlson Comorbidity IndexBMC Cancer 2006, 6:189 http://www.biomedcentral.com/1471-2407/6/189
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since the mortality ratio adjusted for these factors did not
change substantially from the crude mortality ratio. These
findings agree with the limited studies available on the
prognosis of patients who have both cancer and VTE
reported by Sorensen et al [6].
It seems unlikely that complications of VTE, such as recur-
rent VTE and pulmonary embolism, can account entirely
for the increased mortality rate found in our study. An
explanation for our findings could be that the tumours in
the VTE patients were more aggressive in some fashion
that was not captured by the stage information. About 7%
of epithelial ovarian cancers are histopathologically typed
as clear cell adenocarcinoma [18]. This type is known to
be more aggressive than other types despite being often
identified at an early clinical stage [19]. Furthermore, this
histopathologic type has also been associated with VTE
[20]. However, we did not have access to histopatologic
information and could not address this any further.
Our study had other strengths and limitations. We used
nationwide population-based registries with no losses to
long-term follow-up. Clinicians caring for patients with
VTE could have increased their surveillance for cancer in
these patients because of the known association with can-
cer. However, this increased surveillance should have
resulted in earlier diagnosis in the patients with VTE com-
pared to ovarian cancer patients without VTE. In addition,
patients in whom ovarian cancer was diagnosed more
than four months after VTE had a stage distribution
shifted towards more advanced stages compared with
ovarian cancer patients without VTE. Therefore, surveil-
lance bias is unlikely to be a problem in our study. The
ovarian cancer patients were identified in the Danish Can-
cer Registry, which is known to have a completeness of
more than 95% [10]. The diagnosis of VTE can be difficult,
however, and the diagnosis from the Danish Hospital Dis-
charge Registry is known to be misclassified in 10 to 20%
of the cases [21]. This lack of specificity may lead to an
underestimated difference between the patients with VTE
and those without it. The FIGO classification was missing
in 7% to 13% of the patients. Furthermore, there can be
some problems with the validity of the FIGO staging,
since not all of the ovarian cancer patients in Denmark are
staged and surgically treated by an oncological gynaecolo-
gist [22]. These shortcomings allowed for only partial con-
trol of differences in tumour aggressiveness, and may
account for part of the observed difference in mortality
rate.
Unadjusted Kaplan-Meier survival curves for patients in  whom ovarian cancer was diagnosed less than four months  after an episode of VTE versus ovarian cancer patients with- out VTE Figure 1
Unadjusted Kaplan-Meier survival curves for patients in 
whom ovarian cancer was diagnosed less than four months 
after an episode of VTE versus ovarian cancer patients with-
out VTE.
Table 2: FIGO stage of ovarian cancer, according to the presence or absence of venous thromboembolism.
Extent of stage Ovarian cancer 
without VTE 
Ovarian cancer less than 4 months after 
VTE 
Ovarian cancer 4 months to 27 years 
after VTE 
(n = 12,707) (n = 50) (n = 78)
Prevalence Ratio (95% 
CI)a
Prevalence Ratio (95% 
CI)a
Patients with data 
on stage
11,946 (94%) 47 (94%) 68 (87%)
Stage I 1,432 (12%) 3 (6%) 9 (13%)
Stage II 1,600 (13%) 8 (17%) 7 (10%)
Stage III 5,229 (44%) 20 (43%) 28 (41%)
Stage IV 3,685 (31%) 16 (34%) 1.1 (0.8–1.5) 24 (35%) 1.1 (0.8–1.5)
Because of rounding, not all column percentages total 100%. Percentages for patients with data on stage are of the entire group of patients. 
Percentages for patients in the stage categories are of patients with data.
aThe prevalence ratio is the prevalence of patients with stage IV and VTE divided by the prevalence of patients with stage IV and no VTE, adjusted 
for age.BMC Cancer 2006, 6:189 http://www.biomedcentral.com/1471-2407/6/189
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We lacked information on clinical details such as treat-
ment. If VTE or other diseases associated with VTE con-
traindicate effective ovarian cancer therapy, then
differences in received therapies could explain part of the
differences in mortality rates.
In this study we examined all-cause mortality but we did
not address cause-specific mortality. However, we find
that all-cause mortality is a robust measure, because it is
very difficult to distinguish between the contribution of
the ovarian cancer and that of the underlying diseases or
complications to ovarian cancer.
Another explanation to the increased mortality could be
that the coagulation mechanism is implicated in the
pathogenesis of cancer. Recent studies suggest that low-
molecular-weight-heparin (LMWH) therapy in malig-
nancy may improve cancer survival in general [23-25].
Whereas another study did not find a significantly
improved one-year survival in patients with advanced
malignancy treated with dalteparin (5,000 IU), a low
molecular weight heparin [26]. Our study lacked informa-
tion about antithrombotic treatment, so we could not
examine the impact of the type of antithrombotic treat-
ment on mortality among VTE patients. Our data in com-
bination with the studies of antithrombotics do, however,
provide an impetus for further studies of antithrombotic
treatment of ovarian cancer patients.
Conclusion
Our data showed that ovarian cancer diagnosed less than
four months before VTE was associated with an advanced
stage and the prognosis tends to be poorer than for ovar-
ian cancer patients without VTE. The observed differences
in mortality may arise from real differences in the progno-
sis of ovarian cancer patients with and without VTE, but
might also be influenced by the biology of the ovarian
cancers associated with VTE. These findings may have
implications for the clinical care of patients with ovarian
cancer.
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